FluMist manufacturing facility cited
Executive Summary
FDA issues MedImmune a warning letter citing the company for manufacturing deficiencies at its Liverpool, U.K. facility, including failure to implement a program to control microbial contamination of eggs used to make FluMist. FDA does not expect lower availability of the flu vaccine for the 2007-2008 flu season, unlike the 2004-2005 season when GMP violations by Chiron caused a shortage...
You may also be interested in...
FDA Relaxes Restrictions on Live Vaccine Processing
Manufacturers of live vaccines such as those for influenza will soon be able to rely solely on process controls and, where necessary, process containment, to prevent cross-contamination of live vaccine organisms, under a recent direct final rule by FDA
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.